CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 69 enrolled
Drug / intervention
LY900014 U-200 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03616977
NCT03616977Phase 1Completed
CompareCT.gov

Bioequivalence Study Comparing 2 Formulations of LY900014 in Healthy Subjects

Eli Lilly and Company·interventional·Posted Aug 6, 2018·Updated Apr 30, 2020

In Brief

A Phase 1 clinical trial evaluating LY900014 U-200 and LY900014 U-100 for Healthy. Completed, enrolled 69 participants across 1 site.

Detailed Summary

The study involves a comparison of 2 formulations of LY900014, which is a type of fast acting insulin. Study participants will be administered LY900014 U-100 two times and LY900014 U-200 two times, over 4 study periods, by injection under the skin. Blood samples will be taken to compare how the body handles the study drugs and how they affect the blood sugar levels. Side effects and tolerability will be documented. The study will last about 4 weeks, not including screening and follow up. Screening is required within 28 days prior to the start of the study and follow up is required at least 2 weeks after the last dose of study drug.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesSingapore
Collaborators--

Timeline

Phase 1CompletedFinished
20192020202120222023202420252026
First PostedAug 6, 2018
Enrollment StartAug 3, 2018
Primary CompletionOct 19, 2018
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 7.9 years ago

Interventions

LY900014 U-200drug

Administered SC

LY900014 U-100drug

Administered SC